Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EphA4 signaling is involved in the phenotype of well-differentiated oral squamous cell arcinoma with decreased tumor immunity.

European journal of pharmacology - 15 Apr 2023

Kina Shinichiro, Kawabata-Iwakawa Reika, Miyamoto Sho, Kato Tomoki, Kina-Tanada Mika, Arasaki Akira

Abstract excerpt

Metronomic chemotherapy is defined as a high-frequency low-dose schedule of chemotherapy drug administration. Although metronomic chemotherapy is widely used, the mechanisms underlying resistance to metronomic chemotherapy remain unclear. Therefore, we herein conducted a single institutional phase I/II trial to assess the efficacy and safety of metronomic chemotherapy with bleomycin plus S-1, an oral 5-FU...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Squamous Cell
Share to Epithelial Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Head and Neck Neoplasms

Share to Mouth Neoplasms

Share to Phenotype

Share to Squamous Cell Carcinoma of Head and Neck

Share to Tumor Microenvironment

Source

Identifiers

PMID: 36804938
DOI: 10.1016/j.ejphar.2023.175611

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EphA4 signaling is involved in the phenotype of well-differentiated oral squamous cell arcinoma with decreased tumor immunity.PMID 36804938Read ↗

Molecular Profiling of Exceptional Responders to Cancer Therapy.Semantic proximity Read ↗

Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer typesSemantic proximity Read ↗

Systematic Pan-Cancer Analysis Reveals the Prognostic Value and Immunological Role of EPHX2Semantic proximity Read ↗

Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.Semantic proximity Read ↗

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.Semantic proximity Read ↗

Esophageal squamous cell carcinoma with EP300 mutations displays distinct genetic characteristics relevant to neoadjuvant chemoradiotherapy.Semantic proximity Read ↗

Pathways with an impact on effects of metronomic chemotherapy with a fluoropyrimidine prodrug, S-1Semantic proximity Read ↗

Aberrant Hippo-YAP/TEAD signaling drives malignant transcriptional reprogramming in external auditory canal squamous cell carcinomaSemantic proximity Read ↗

EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.Semantic proximity Read ↗

When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors.Semantic proximity Read ↗

The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinomaSemantic proximity Read ↗

RacGAP1 Is a Novel Downstream Effector of E2F7-Dependent Resistance to Doxorubicin and Is Prognostic for Overall Survival in Squamous Cell CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.